{"hq_id":"hq-p-spe-000008","name":"Generic Valsartan, Ranitidine (Zantac), and Metformin (NDMA Pharmaceutical Recalls 2018–2020)","category":{"primary":"personal_care","secondary":"","tags":[]},"product_tier":"SPE","overall_risk_level":"low","description":"NDMA was not detected in generic valsartan for years because no one tested for it. It was not on the standard impurity panel.","synthesis":{"derived_risk_level":"high","synthesis_confidence":0.82,"synthesis_method":"compound_composition","context_used":"human_adult","context_source":"product_users","exposure_modifier":0.977,"vulnerability_escalated":false,"escalation_reason":null,"compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-03-27","synthesis_version":"1.0.0"},"hazard_summary":{"sensitive_populations":"Millions of patients taking valsartan, metformin, ranitidine; elderly with multiple comorbidities; pregnant women","overall_risk":"low","primary_concerns":["Largest pharmaceutical recall series in FDA history; NDMA at 180–1,800× FDA acceptable daily intake; ranitidine molecule itself generates NDMA during normal storage; detected only by accidental discovery"],"exposure_routes":"Chronic pharmaceutical exposure; daily long-term medication for hypertension, GERD, diabetes"},"exposure":{"routes":["dermal"],"contact_types":["oral_direct"],"users":["adult"],"duration":"minutes","frequency":"daily","scenarios":["Dermal contact during handling of Generic Valsartan, Ranitidine (Zantac), and Metformin (NDMA Pharmaceutical Recalls 2018–2020) (minutes contact)"],"notes":"Exposure to Generic Valsartan, Ranitidine (Zantac), and Metformin (NDMA Pharmaceutical Recalls 2018–2020) occurs via dermal."},"consumer_guidance":{"red_flags":[{"indicator":"Identified safety concern","meaning":"Largest pharmaceutical recall series in FDA history; NDMA at 180–1,800× FDA acceptable daily intake; ranitidine molecule itself generates NDMA during normal storage; detected only by accidental dis...","action":"Review safety data; follow use guidelines; consider alternatives"}],"green_flags":[{"indicator":"Third-party safety tested","meaning":"Independent laboratory verification of safety claims","verification":"Check for recognized certification marks and test reports"}],"what_to_ask":[{"question":"What safety testing has this product undergone?","why_it_matters":"Third-party testing provides independent verification of safety claims"}],"alternatives":[{"name":"Losartan or Olmesartan","notes":"Alternative ARBs not affected by NDMA recall"},{"name":"Famotidine (Pepcid)","notes":"H2 blocker without NDMA contamination issues"},{"name":"Extended-release Metformin","notes":"Formulations from unaffected manufacturers"}],"notes":null},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA — California","regulation":"California Proposition 65 (Safe Drinking Water and Toxic Enforcement Act of 1986)","citation":null,"requirements":"Products containing chemicals on the Prop 65 list require clear and reasonable warnings if exposure exceeds safe harbor levels. Applies to products sold in California.","compliance_status":null,"effective_date":null,"enforcing_agency":null,"penalties":null,"source_ref":null},{"jurisdiction":"EU","regulation":"REACH Regulation (EC) No 1907/2006","citation":null,"requirements":"Registration, Evaluation, Authorisation and Restriction of Chemicals. Articles containing SVHCs >0.1% w/w must notify ECHA and inform consumers on request.","compliance_status":null,"effective_date":null,"enforcing_agency":null,"penalties":null,"source_ref":null}],"certifications":[{"name":"FDA Drug","issuer":"FDA","standard":"21 CFR Parts 200-299","scope":"Drug safety, labeling, and manufacturing standards"}],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Drug take-back programs; FDA flush list for dangerous medications; do not flush most medications","hazardous_waste":false,"expected_lifespan":"months"},"formulation":{"form":"composite_material","key_ingredients":[{"hq_id":null,"name":"Primary component","role":"base_material","concentration_pct":"70-80"},{"hq_id":null,"name":"Secondary component","role":"additive","concentration_pct":"10-20"},{"hq_id":null,"name":"Filler or coating","role":"filler","concentration_pct":"5-10"}],"certifications":[]},"materials":{"common":[{"material_id":"hq-m-chm-000080","material_name":"NDMA/N-Nitrosamine Contamination in Generic Pharmaceutical Manufacturing","component":null,"prevalence":"common"}],"concerning":[{"material_id":"hq-m-chm-000080","concern":"Valsartan (blood pressure): ~150 million prescriptions affected; Zhejiang Huahai (China) supplied generic valsartan to US and global markets; NDMA 17–177 ppm measured (180–1,800× FDA acceptable daily intake 0.096 µg)","compounds_of_concern":[],"source_refs":[]},{"material_id":"hq-m-chm-000080","concern":"Ranitidine (Zantac): 38-year market history; molecule itself generates NDMA during normal storage; worldwide withdrawal April 2020; largest pharmaceutical recall in FDA history; every bottle on every pharmacy shelf contaminated (not lot-specific)","compounds_of_concern":[],"source_refs":[]},{"material_id":"hq-m-chm-000080","concern":"Metformin (~87 million annual US prescriptions): FDA TDI 0.096 µg; discovered to contain NDMA; systemic oversight insufficient for detecting process-related contaminants","compounds_of_concern":[],"source_refs":[]},{"material_id":"hq-m-chm-000080","concern":"Regulatory gap: NDMA not on standard impurity panel; detected only by accidental discovery (Valisure); no mandatory testing before contamination was known","compounds_of_concern":[],"source_refs":[]},{"material_id":"hq-m-chm-000080","concern":"Potential contaminant: NDMA co-contaminants (NDEA, NMBA, NIPEA)","compounds_of_concern":["hq-c-org-000015"],"source_refs":[]}],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000015","compound_name":"NDMA (N-nitrosodimethylamine)","role":"base","typical_concentration":null}],"identifiers":{"common_names":["blood pressure medication","heartburn medication","diabetes medication"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[{"brand":"Generic Mass-Market Brand A","manufacturer":"Consumer Products Corporation","market_position":"mass_market","notable":"Widely available mass-market option"},{"brand":"Generic Mass-Market Brand B","manufacturer":"Consumer Goods Ltd","market_position":"mass_market","notable":"Popular budget alternative"},{"brand":"Premium Brand A","manufacturer":"Premium Consumer Inc","market_position":"premium","notable":"Upscale premium positioning"},{"brand":"Professional Brand","manufacturer":"Professional Products Co","market_position":"professional","notable":"Professional/salon-grade option"},{"brand":"Specialty Eco-Brand","manufacturer":"Natural Products Ltd","market_position":"premium","notable":"Sustainable/natural product line"}],"sources":[{"id":"src_001","type":"regulatory","title":"FDA Valsartan Recall and NDMA Contamination (July 2018 onwards)","year":2018},{"id":"src_002","type":"journal","title":"Ranitidine Spontaneous Degradation to NDMA (Valisure Investigation, October 2019)","year":2019},{"id":"src_003","type":"regulatory","title":"FDA Worldwide Ranitidine Withdrawal (April 2020)","year":2020}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-25","timestamp":"2026-05-02T18:15:59.806Z"}}